Epidemiology of Systemic Mycoses in the COVID-19 Pandemic

• Published in: Journal of fungi (Basel) Vol. 7; no. 7; p. 556
• Main Authors: Frías-De-León, María Guadalupe, Pinto-Almazán, Rodolfo, Hernández-Castro, Rigoberto, García-Salazar, Eduardo, Meza-Meneses, Patricia, Rodríguez-Cerdeira, Carmen, Arenas, Roberto, Conde-Cuevas, Esther, Acosta-Altamirano, Gustavo, Martínez-Herrera, Erick
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 13.07.2021; MDPI
• Subjects: Antifungal agents; Aspergillosis; Asthma; Candidiasis; Chronic obstructive pulmonary disease; co-infection; Coccidioidomycosis; Colonization; Coronaviruses; COVID-19; Cytokines; Diabetes; Disease; Dyspnea; Epidemiology; Fatalities; Fungal infections; Fungi; Histoplasmosis; HIV; Hospitalization; Human immunodeficiency virus; Immunosuppression; Inflammation; Lungs; Lymphocytes T; Melanoma; Mucormycosis; Mycosis; Pandemics; Patients; Pneumocystosis; Pneumonia; Review; Risk factors; Severe acute respiratory syndrome coronavirus 2; systemic mycoses; T cell receptors; Tumor necrosis factor-TNF; Ventilators; Women; COVID-19; co-infection; endemic mycosis; systemic mycoses; aspergillosis; pneumocystosis; candidiasis; mucormycosis
• ISSN: 2309-608X; 2309-608X
• DOI: 10.3390/jof7070556

The physiopathologic characteristics of COVID-19 (high levels of inflammatory cytokines and T-cell reduction) promote fungal colonization and infection, which can go unnoticed because the symptoms in both diseases are very similar. The objective of this work was to study the current epidemiology of systemic mycosis in COVID-19 times. A literature search on the subject (January 2020-February 2021) was performed in PubMed, Embase, Cochrane Library, and LILACS without language restrictions. Demographic data, etiological agent, risk factors, diagnostic methods, antifungal treatment, and fatality rate were considered. Eighty nine publications were found on co-infection by COVID-19 and pneumocystosis, candidiasis, aspergillosis, mucormycosis, coccidioidomycosis, or histoplasmosis. In general, the co-infections occurred in males over the age of 40 with immunosuppression caused by various conditions. Several species were identified in candidiasis and aspergillosis co-infections. For diagnosis, diverse methods were used, from microbiological to molecular. Most patients received antifungals; however, the fatality rates were 11-100%. The latter may result because the clinical picture is usually attributed exclusively to SARS-CoV-2, preventing a clinical suspicion for mycosis. Diagnostic tests also have limitations beginning with sampling. Therefore, in the remainder of the pandemic, these diagnostic limitations must be overcome to achieve a better patient prognosis.